ECTE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ECTE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Echo Therapeutics's average diluted shares outstanding for the quarter that ended in Sep. 2016 was 17.26 Mil.
The historical data trend for Echo Therapeutics's Shares Outstanding (Diluted Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Echo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Shares Outstanding (Diluted Average) | Get a 7-Day Free Trial | 3.42 | 3.96 | 8.36 | 12.31 | 11.23 |
Echo Therapeutics Quarterly Data | ||||||||||||||||||||
Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Shares Outstanding (Diluted Average) | Get a 7-Day Free Trial | 11.13 | 11.13 | 11.22 | 11.45 | 17.26 |
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Echo Therapeutics (OTCPK:ECTE) Shares Outstanding (Diluted Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Thank you for viewing the detailed overview of Echo Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael M Goldberg | director | C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Uri Landesman | 10 percent owner | 230 PARK AVENUE, NEW YORK NY 10169 |
Platinum Partners Value Arbitrage Fund, Lp | 10 percent owner | 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019 |
Mark Nordlicht | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum Management (ny) Llc | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum-montaur Life Sciences, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Partners Liquid Opportunity Master Fund L.p. | 10 percent owner | 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Liquid Opportunity Management (ny) Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Bernhardt Charles Thomas Iii | officer: Interim CFO | 23 BIRCH ROAD, MALVERN PA 19355 |
Vincent D Enright | director | ONE CORPORATE CENTER, RYE NY 10580 |
William Grieco | director | 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Robert F Doman | director, officer: EXEC. CHAIRMAN AND INTERIM CEO | C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887 |
Patrick T Mooney | director, officer: CEO AND PRESIDENT | C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038 |
Christopher P. Schnittker | officer: CFO | 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.